Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1‐mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma

Hua Tian, Chao Ge, Hong Li, Fangyu Zhao, Helei Hou, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li – 9 November 2013 – Ribonucleotide reductase (RR)M2B is an enzyme belonging to the ribonucleotide reductase enzyme family, which is essential for DNA synthesis and repair. RRM2B plays an important role in tumor progression and metastasis; however, little is known about the expression and underlying molecular mechanisms of RRM2B in hepatocellular carcinoma (HCC).

T‐cell factor 4 and β‐catenin chromatin occupancies pattern zonal liver metabolism in mice

Angélique Gougelet, Cyril Torre, Philippe Veber, Chiara Sartor, Laura Bachelot, Pierre‐Damien Denechaud, Cécile Godard, Marthe Moldes, Anne‐Françoise Burnol, Céline Dubuquoy, Benoit Terris, François Guillonneau, Tao Ye, Michael Schwarz, Albert Braeuning, Christine Perret, Sabine Colnot – 9 November 2013 – β‐catenin signaling can be both a physiological and oncogenic pathway in the liver. It controls compartmentalized gene expression, allowing the liver to ensure its essential metabolic function.

Antibody‐mediated rejection as a contributor to previously unexplained early liver allograft loss

Jacqueline G. O'Leary, Hugo Kaneku, Anthony J. Demetris, John D. Marr, S. Michelle Shiller, Brian M. Susskind, Glenn W. Tillery, Paul I. Terasaki, Göran B. Klintmalm – 6 November 2013 – We analyzed 60 patients with idiopathic early allograft loss (defined as death or retransplantation at <90 days) to determine the relative contribution of preformed donor‐specific human leukocyte antigen alloantibodies (DSAs) to this endpoint, and we defined strict criteria for the diagnosis of antibody‐mediated rejection (AMR) in liver allografts.

Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation

Adeeb Salah, Masakazu Fujimoto, Atsushi Yoshizawa, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Shinji Sumiyoshi, Sachiko Minamiguchi, Shinji Uemoto, Taira Maekawa, Hironori Haga – 6 November 2013 – Antibody‐mediated rejection (AMR) is difficult to diagnose after ABO‐compatible or ABO‐identical (ABO‐C) liver transplantation. To determine whether complement component 4d (C4d) immunostaining would be useful for diagnosing AMR, we compared the results of C4d immunohistochemistry for allograft biopsy samples with assays for anti‐donor antibodies performed at the time of biopsy.

Subscribe to